O

Obio Technology Shanghai Corp Ltd
SSE:688238

Watchlist Manager
Obio Technology Shanghai Corp Ltd
SSE:688238
Watchlist
Price: 5.48 CNY -6.16% Market Closed
Market Cap: 3.5B CNY
Have any thoughts about
Obio Technology Shanghai Corp Ltd?
Write Note

Obio Technology Shanghai Corp Ltd
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Obio Technology Shanghai Corp Ltd
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
O
Obio Technology Shanghai Corp Ltd
SSE:688238
Total Liabilities & Equity
ÂĄ2.6B
CAGR 3-Years
40%
CAGR 5-Years
71%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Total Liabilities & Equity
ÂĄ74.4B
CAGR 3-Years
13%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Total Liabilities & Equity
ÂĄ23B
CAGR 3-Years
11%
CAGR 5-Years
34%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Total Liabilities & Equity
ÂĄ56.1B
CAGR 3-Years
9%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Total Liabilities & Equity
ÂĄ30.4B
CAGR 3-Years
11%
CAGR 5-Years
37%
CAGR 10-Years
38%
W
WuXi XDC Cayman Inc
HKEX:2268
Total Liabilities & Equity
ÂĄ6.7B
CAGR 3-Years
155%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Obio Technology Shanghai Corp Ltd
Glance View

Market Cap
3.5B CNY
Industry
Life Sciences Tools & Services

Obio Technology Shanghai Corp. Ltd. engages in biomedical basic research, gene therapy drug incubation, and clinical grade gene therapy virus vector CDMO service provision. The company is headquartered in Shanghai, Shanghai and currently employs 631 full-time employees. The company went IPO on 2022-03-22. The firm is mainly engaged in providing contract research organization (CRO) services such as gene therapy vector development and gene function research for the basic research of gene therapy, as well as contract research and development production organization (CDMO) services such as pharmaceutical research and clinical sample production for the research and development of gene drugs. The firm mainly conducts business in the European and American markets and the domestic market.

Intrinsic Value
4.5 CNY
Overvaluation 18%
Intrinsic Value
Price
O

See Also

What is Obio Technology Shanghai Corp Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
2.6B CNY

Based on the financial report for Dec 31, 2023, Obio Technology Shanghai Corp Ltd's Total Liabilities & Equity amounts to 2.6B CNY.

What is Obio Technology Shanghai Corp Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
71%

Over the last year, the Total Liabilities & Equity growth was 4%. The average annual Total Liabilities & Equity growth rates for Obio Technology Shanghai Corp Ltd have been 40% over the past three years , 71% over the past five years .

Back to Top